- Home
- NBIX vs JEF Comparison
NBIX vs JEF Comparison
Compare NBIX & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBIX | JEF |
|---|---|---|
| Founded | 1992 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 10.5B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBIX | JEF |
|---|---|---|
| Price | $155.43 | $59.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $173.79 | $71.00 |
| AVG Volume (30 Days) | 969.9K | ★ 1.7M |
| Earning Date | 10-28-2025 | 01-07-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | 12.44 | ★ 25.06 |
| EPS | ★ 4.19 | 2.92 |
| Revenue | $2,682,700,000.00 | ★ $7,231,501,000.00 |
| Revenue This Year | $23.76 | $5.85 |
| Revenue Next Year | $18.01 | $9.97 |
| P/E Ratio | $37.10 | ★ $20.42 |
| Revenue Growth | ★ 19.61 | 15.68 |
| 52 Week Low | $84.23 | $39.28 |
| 52 Week High | $157.67 | $82.68 |
Technical Indicators
Market Signals| Indicator | NBIX | JEF |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 60.60 |
| Support Level | $150.26 | $55.98 |
| Resistance Level | $154.35 | $58.25 |
| Average True Range (ATR) | 4.16 | 2.07 |
| MACD | 1.07 | 0.54 |
| Stochastic Oscillator | 93.25 | 89.10 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About JEF Jefferies Financial Group Inc.
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.